# Choosing the Best Antibiotic to Protect Friendly Gut Bacteria During the Course of Stem Cell Transplant

> **NCT03078010** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 347 (actual)

## Conditions studied

- Intestinal Microbiome
- Febrile Neutropenia

## Interventions

- **DRUG:** Piperacillin-tazobactam
- **DRUG:** cefepime

## Key facts

- **NCT ID:** NCT03078010
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-02-10
- **Primary completion:** 2027-02
- **Final completion:** 2027-02
- **Target enrollment:** 347 (ACTUAL)
- **Last updated:** 2026-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03078010

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03078010, "Choosing the Best Antibiotic to Protect Friendly Gut Bacteria During the Course of Stem Cell Transplant". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03078010. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*